Company Description
Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States.
The company, through its Tumorgraft technology platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice.
It also offers translational oncology solutions that utilizes its technology platform to provide research services that assist in the drug development process of pharmaceutical and biotechnology companies.
In addition, the company offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies.
It markets its products through internet and sales force to pharmaceutical and biotechnology companies.
The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011.
Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
| Country | United States |
| Founded | 1985 |
| IPO Date | Mar 25, 1986 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 213 |
| CEO | Robert Brainin |
Contact Details
Address: One University Plaza, Suite 307 Hackensack, New Jersey 07601 United States | |
| Phone | 201 808 8400 |
| Website | championsoncology.com |
Stock Details
| Ticker Symbol | CSBR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | May - April |
| Reporting Currency | USD |
| CIK Code | 0000771856 |
| CUSIP Number | 15870P307 |
| ISIN Number | US15870P3073 |
| Employer ID | 52-1401755 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Robert Brainin | Chief Executive Officer and Director |
| Dr. Ronnie Morris M.D. | Executive Chair |
| David Barry Miller M.B.A. | Chief Financial Officer |
| Dr. Maria Mancini Ph.D. | Chief Operating Officer |
| Gavin Cooper | Vice President of Global Marketing |
| Dr. Marianna Zipeto Ph.D. | Executive Vice President of Commercial, Research Services and Partnering |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 16, 2025 | 8-K | Current Report |
| Sep 15, 2025 | 10-Q | Quarterly Report |
| Sep 15, 2025 | 8-K | Current Report |
| Aug 22, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Aug 22, 2025 | DEF 14A | Other definitive proxy statements |
| Jul 23, 2025 | 10-K | Annual Report |
| Jul 23, 2025 | 8-K | Current Report |
| Jul 21, 2025 | 8-K | Current Report |
| Mar 17, 2025 | 10-Q | Quarterly Report |
| Mar 11, 2025 | 8-K | Current Report |